Referring to an EphA4 Antibody or a fragment of EphA4 Binding to the sameComprising: (a) CDR H1 - comprising the Amino Acid Sequence represented by SEQ ID no: 26 or SEQ ID no: 27 (b) cor - H2 comprising the Amino Acid Sequence represented by SEQ ID no: 28 or SEQ ID no: 29 (c) CDR H3 comprising the Amino Acid Sequence represented by SEQ ID no: 30 (d) cor - L1 comprising the Amino Acid Sequence represented by SEQ ID no: 31 e) cor - L2Comprising the Amino Acid Sequence represented by SEQ ID no: 32 and (f) CDR L3 comprising the Amino Acid Sequence represented by SEQ ID no: 33.Where the Antibody is able to bind the same EphA4 and inhibit the binding between EphA4 and its ligand.Also refers to the identification of sequences of complementarity determining Regions (CDRs) of EphA4 Antibody anti mouseAnd the preparation comprises that a Humanized Antibody Antibody antiepha4 CDR sequences of mouse in the variable region of the heavy chain and the light chain variable region. Used for the treatment of Amyotrophic Lateral Sclerosis (ALS).Referido a un anticuerpo anti-EphA4 o un fragmento de union a EphA4 del mismo, que comprende: a) CDR-H1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 26 o la SEQ ID NO: 27 b) CDR-H2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 28 o la SEQ ID NO: 29 c) CDR-H3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 30 d) CDR-L1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 31 e) CDR-L2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 32 y f) CDR-L3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 33. En donde dicho anticuerpo es capaz de unirse a EphA4 del mismo e inhibir la union entre EphA4 y su ligando. Tambien se refiere la identificacion de las secuencias de regiones determinantes de complementariedad (CDRs) del anticuerpo anti-EphA4 de raton, y a la preparacion de un anticuerpo humanizado que comprende las secuenc
